Roivant Sciences Ltd. $ROIV Shares Sold by Inceptionr LLC

Inceptionr LLC lowered its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 48.4% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 20,842 shares of the company’s stock after selling 19,568 shares during the quarter. Inceptionr LLC’s holdings in Roivant Sciences were worth $577,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Pictet Asset Management Holding SA grew its stake in shares of Roivant Sciences by 790.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock worth $50,180,000 after purchasing an additional 2,052,693 shares during the period. Capricorn Fund Managers Ltd boosted its holdings in Roivant Sciences by 124.4% during the fourth quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock worth $9,667,000 after buying an additional 247,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after buying an additional 3,254,113 shares in the last quarter. Exchange Traded Concepts LLC acquired a new stake in Roivant Sciences during the fourth quarter valued at $5,435,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of Roivant Sciences by 90.9% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 80,561 shares of the company’s stock worth $1,746,000 after acquiring an additional 38,354 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ROIV. Guggenheim increased their target price on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Leerink Partners set a $42.00 price objective on Roivant Sciences in a report on Thursday, May 21st. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Finally, Citigroup upped their target price on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $35.01 on Friday. The stock has a market capitalization of $25.18 billion, a P/E ratio of -58.35 and a beta of 1.11. The business has a 50 day simple moving average of $32.24 and a two-hundred day simple moving average of $28.62. Roivant Sciences Ltd. has a 12 month low of $10.90 and a 12 month high of $37.00.

Insider Buying and Selling at Roivant Sciences

In other news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at $53,489,169.08. The trade was a 11.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the sale, the director owned 16,474 shares of the company’s stock, valued at $566,376.12. This represents a 51.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,855,913 shares of company stock worth $62,649,633. Corporate insiders own 10.80% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.